BPMC News and Press, Blueprint Medicines Corporation From 01/12/20

Deals and Financings Apollomics of Hangzhou announced a $189 million agreement to develop two GlycoMimetics (GLYC) novel E-selectin-based immunotherapies in China for leukemia. Apollomics, which was incubated by OrbiMed Asia, will be responsible for developing uproleselan and GMI-1687 in...

CAMBRIDGE, Mass. , Jan. 9, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has approved A...

Blueprint Medicines (NASDAQ: BPMC ) initiates its rolling NDA filing for pralsetinib (BLU-667) for RET fusion-positive non-small cell lung cancer (NSCLC). It expects to complete the submission this quarter. More news on: Blueprint Medicines Corporation, Healthcare stocks news, Stocks on ...

CAMBRIDGE, Mass. , Jan. 8, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced independent centrally reviewed top-line data for pralsetinib in ...

Quick Take Black Diamond Therapeutics ( BDTX ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement . The company is developing a platform that identifies small molecule kinase inhibitors, which help to slow or stop cancer. BDTX is a ...

SUZHOU, China and CAMBRIDGE, Mass. , Jan. 6, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company focused on developing and commercializing immuno-oncology and precision medicines, and Blueprint Medicines Corporation (NASDAQ: BPMC), a precision...

Welcome to a special New Year's Day edition of Seeking Alpha's Stocks to Watch series - a preview of some key events and catalysts to look for in the new year. A podcast of Stocks to Watch is available every Sunday on Seeking Alpha , Apple Podcasts , Stitcher and Spotify (click the highl...

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 11/13/2019. Please visit our Tracking Ole Andreas Halvorsen&#...

Biotech investors are on the edge of their seats this holiday season thanks to a recent string of juicy buyout offers. Despite a busy year for acquisitions, big pharmaceutical companies with pipelines to fill and money to spend have been jumping over each other to acquire smaller biotechs at ste...

Merck's $2.7B bid for ArQule is yet another example of the Big Biopharma's high regard for oral kinase inhibitors for treating cancer. ArQule's lead drug is ARQ 531, an oral inhibitor of Bruton's tyrosine kinase (BTK). More news on: Pfizer Inc., Eli Lilly and Company, AbbVie Inc., Health...